Nevro Corp. NVRO reported a loss per share of 64 cents in the fourth quarter of 2024, wider than the year-ago quarter’s loss ...

During the fourth quarter of 2024, Nevro made significant advancements in its product offerings and market expansion. The company launched the full market release of HFX iQ with HFX AdaptivAI ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...

Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes the Senza® SCS system and support services for the treatment of chronic pain of the trunk and limb and painful ...

Patents covering Senza HFX iQ and other Nevro products are listed at Nevro/patents . To learn more about Nevro, visit and connect with us on LinkedIn , X , Facebook , and Instagram . Forward ...

Nevro's comprehensive HFX spinal cord stimulation (SCS) platform includes the Senza® SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic ...

Nevro has also focused on advancing its product portfolio. The launch of the HFX AdaptivAI platform in the U.S. in November 2024 represents a significant step in this direction. Additionally ...